272 related articles for article (PubMed ID: 17883951)
1. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
[TBL] [Abstract][Full Text] [Related]
2. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
3. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
4. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
5. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.
Krug A; Rothenfusser S; Hornung V; Jahrsdörfer B; Blackwell S; Ballas ZK; Endres S; Krieg AM; Hartmann G
Eur J Immunol; 2001 Jul; 31(7):2154-63. PubMed ID: 11449369
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells.
Lenert P; Rasmussen W; Ashman RF; Ballas ZK
DNA Cell Biol; 2003 Oct; 22(10):621-31. PubMed ID: 14611683
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages.
Yu D; Kandimalla ER; Zhao Q; Cong Y; Agrawal S
Bioorg Med Chem; 2001 Nov; 9(11):2803-8. PubMed ID: 11597460
[TBL] [Abstract][Full Text] [Related]
8. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
9. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
Zelenay S; Elías F; Fló J
Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
[TBL] [Abstract][Full Text] [Related]
11. Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs.
Zhao H; Cheng SH; Yew NS
Antisense Nucleic Acid Drug Dev; 2000 Oct; 10(5):381-9. PubMed ID: 11079577
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications.
Zimmermann S; Heeg K; Dalpke A
Vaccine; 2003 Feb; 21(9-10):990-5. PubMed ID: 12547613
[TBL] [Abstract][Full Text] [Related]
13. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.
Verthelyi D; Ishii KJ; Gursel M; Takeshita F; Klinman DM
J Immunol; 2001 Feb; 166(4):2372-7. PubMed ID: 11160295
[TBL] [Abstract][Full Text] [Related]
14. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.
Zwiorek K; Bourquin C; Battiany J; Winter G; Endres S; Hartmann G; Coester C
Pharm Res; 2008 Mar; 25(3):551-62. PubMed ID: 17912489
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.
Britigan BE; Lewis TS; Waldschmidt M; McCormick ML; Krieg AM
J Immunol; 2001 Sep; 167(5):2921-8. PubMed ID: 11509640
[TBL] [Abstract][Full Text] [Related]
16. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM
J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
[TBL] [Abstract][Full Text] [Related]
18. Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung.
Yamada H; Ishii KJ; Klinman DM
Crit Care Med; 2004 Oct; 32(10):2045-9. PubMed ID: 15483413
[TBL] [Abstract][Full Text] [Related]
19. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.
Bjersing JL; Eriksson K; Tarkowski A; Collins LV
Inflammation; 2004 Feb; 28(1):39-51. PubMed ID: 15072229
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of immunological activity of CpG ODN by chitosan gene carrier.
Xiang Y; Yu Q; Qi Z; Du Z; Xu S; Zhang H
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):128-30. PubMed ID: 17497276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
